Denosumab
Contents
Description
Denosumab is a fully human monoclonal antibody that inhibits RANK ligand, thereby reducing bone resorption and increasing bone density. It is used off-label for polyostotic fibrous dysplasia to reduce skeletal complications and bone pain. The drug has demonstrated efficacy in reducing bone turnover markers in fibrous dysplasia patients.
Indications & Therapeutic Use
Prevention of skeletal-related events in patients with bone metastases, giant cell tumor of bone, polyostotic fibrous dysplasia (off-label)
Global Availability (7 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Denosumab — GNH India
87 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | Denosumab |
| Brands | 1 brand available |
| Active Ingredient | Denosumab |
| Drug Class | Prevention of skeletal-related events in patients with bone metastases |
| Manufacturer | Amgen |
| Dosage Forms | Subcutaneous injection, 120mg/1.7mL solution |
| Medical Code | M05BX04 |
| Orphan Status | No |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00896454 |
| Countries | 7 countries |